The Hive > Novel Discourse
Rhodium:
Stereospecific Requirements for Hallucinogenesis
A. T. Shulgin
J. Pharm. Pharmac. 25, 271-272 (1973) (https://www.thevespiary.org/rhodium/Rhodium/chemistry/shulgin.hallucinogenic.chirality.html)
Rhodium:
Monomethylthio analogs of 1-(2,4,5-trimethoxyphenyl)-2-aminopropane
Peyton Jacob, , III George Anderson, , III Charles K. Meshul, Alexander T. Shulgin, Neal Castagnoli
J. Med. Chem. 20, 1235-1239 (1977) (https://www.thevespiary.org/rhodium/Rhodium/pdf/shulgin/shulgin.monothio.tma-2.analogs.pdf)
Abstract
Regiospecific syntheses of the three monomethylthio analogues of 1-(2,4,5-trimethoxypheny1)-2-aminopropane are described. The three isomeric amines were evaluated for potential psychotomimetic potency using the rabbit hyperthermia assay. Enantiomeric compositions and time-concentration curves in rat brains were determined following intraperitoneal administration of each compound. The biological data are contrasted with the corresponding results obtained with the potent human psychotogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM).
Rhodium:
Centrally Active Phenethylamines
Alexander T. Shulgin & Michael F. Carter
Psychopharm. Commun. 1(1), 93-98 (1975) (https://www.thevespiary.org/rhodium/Rhodium/chemistry/2c-b.2c-d.pharmacology.html)
Abstract
The two-carbon homologs of two potent psychotomimetic agents are described. Unlike the parent isopropylamine compounds (4-methyl-2,5-dimethoxyamphetamine, DOM, STP; and 4-bromo-2,5-dimethoxyamphetamine, PBR, 4-BR) these phenethylamines lead to an intoxication state which is, normal subjects, of short duration and of greatly increased sensory enhancement, but which does not superimpose hallucinogenesis. These two phenethylamines, 4-methyl-2,5-dimethoxyphenethylamine (II) and 4-bromo- 2,5-dimethoxyphenethylamine (III), are active in man at oral levels of 0.1 to 0.2 mg/Kg, approximately one-tenth the potency of their three-carbon counterparts.
____ ___ __ _
A Protocol for the Evaluation of New Psychoactive Drugs in Man
Alexander T. Shulgin, L. Ann Shulgin and Peyton JacobIII
Meth. and Find. Exptl. Clin. Pharmacol. 8(5), 313-320 (1986) (https://www.thevespiary.org/rhodium/Rhodium/chemistry/shulgin.evaluation.protocol.html)
Summary
A protocol is presented that has proven effective in the determination, in man, of the psychotomimetic potency and qualitative nature of action of a new drug. It involves a minimum of animal screening, but relies heavily upon the use of experienced human subjects. This procedure has been successful in the discovery of over 200 novel CNS-active agents.
____ ___ __ _
Characterization of Three New Psychotomimetics
Alexander T. Shulgin & David E. Nichols
In: The Psychopharmacology of Hallucinogens, pp. 74-83 (1978) (https://www.thevespiary.org/rhodium/Rhodium/chemistry/shulgin-nichols.three.new.html)
Ed: Stillman, R. C. Willette, R. E., New York; Pergamon[/u]
Navigation
[0] Message Index
[*] Previous page
Go to full version